CoChat
Sign Up
Cited by 316

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Heart failure drug treatment

Rossignol, Patrick, Hernandez, Adrian F, Solomon, Scott D, Zannad, Faiez·2019·The Lancet
DOI 10.1016/s0140-6736(18)31808-7
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(18)31808-7

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 89

  1. Braunwald, 2013, Heart failure, JACC Heart Fail, 1, 1, 10.1016/j.jchf.2012.10.002 · DOI
  2. Zannad, 2018, Rising incidence of heart failure demands action, Lancet, 391, 518, 10.1016/S0140-6736(17)32873-8 · DOI
  3. Hunt, 2005, Circulation, 112, e154, 10.1161/CIRCULATIONAHA.105.553370 · DOI
  4. Ponikowski, 2016, Eur Heart J, 37, 2129, 10.1093/eurheartj/ehw128 · DOI · Paper page
  5. Yancy, 2013, 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines, Circulation, 128, 1810, 10.1161/CIR.0b013e31829e8807 · DOI · Paper page
  6. Girerd, 2018, Integrative assessment of congestion in heart failure throughout the patient journey, JACC Heart Fail, 6, 273, 10.1016/j.jchf.2017.09.023 · DOI
  7. Ziaeian, 2016, The prevention of hospital readmissions in heart failure, Prog Cardiovasc Dis, 58, 379, 10.1016/j.pcad.2015.09.004 · DOI
  8. Senni, 2014, In-hospital and 1-year outcomes of acute heart failure patients according to presentation (de novo vs worsening) and ejection fraction. Results from IN-HF Outcome Registry, Int J Cardiol, 173, 163, 10.1016/j.ijcard.2014.02.018 · DOI
  9. Bergethon, 2016, Trends in 30-day readmission rates for patients hospitalized with heart failure: findings from the get with the guidelines-heart failure registry, Circ Heart Fail, 9, e002594, 10.1161/CIRCHEARTFAILURE.115.002594 · DOI
  10. Maggioni, 2013, EURObservational Research Programme: regional differences and 1-year follow-up results of the Heart Failure Pilot Survey (ESC-HF Pilot), Eur J Heart Fail, 15, 808, 10.1093/eurjhf/hft050 · DOI
  11. Tromp, 2018, Multimorbidity in patients with heart failure from 11 Asian regions: a prospective cohort study using the ASIAN-HF registry, PLoS Med, 15, e1002541, 10.1371/journal.pmed.1002541 · DOI
  12. Damasceno, 2012, The causes, treatment, and outcome of acute heart failure in 1006 Africans from 9 countries, Arch Intern Med, 172, 1386, 10.1001/archinternmed.2012.3310 · DOI
  13. Dokainish, 2017, Global mortality variations in patients with heart failure: results from the International Congestive Heart Failure (INTER-CHF) prospective cohort study, Lancet Glob Health, 5, e665, 10.1016/S2214-109X(17)30196-1 · DOI
  14. Van Aelst, 2018, Acutely decompensated heart failure with preserved and reduced ejection fraction present with comparable haemodynamic congestion, Eur J Heart Fail, 20, 738, 10.1002/ejhf.1050 · DOI
  15. Harjola, 2018, Eur J Heart Fail, 20, 1081, 10.1002/ejhf.1204 · DOI
  16. Ibrahim, 2018, The future of biomarker-guided therapy for heart failure after the guiding evidence-based therapy using biomarker intensified treatment in heart failure (GUIDE-IT) study, Curr Heart Fail Rep, 15, 37, 10.1007/s11897-018-0381-0 · DOI
  17. Felker, 2017, Effect of natriuretic peptide-guided therapy on hospitalization or cardiovascular mortality in high-risk patients with heart failure and reduced ejection fraction: a randomized clinical trial, JAMA, 318, 713, 10.1001/jama.2017.10565 · DOI
  18. Houston, 2015, Volume overload in heart failure: an evidence-based review of strategies for treatment and prevention, Mayo Clin Proc, 90, 1247, 10.1016/j.mayocp.2015.05.002 · DOI
  19. Colin-Ramirez, 2016, Salt in the diet in patients with heart failure: what to recommend, Curr Opin Cardiol, 31, 196, 10.1097/HCO.0000000000000253 · DOI
  20. Abraham, 2011, Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial, Lancet, 377, 658, 10.1016/S0140-6736(11)60101-3 · DOI · Paper page
  21. Zannad, 2018, Cardiorenal syndrome revisited, Circulation, 138, 929, 10.1161/CIRCULATIONAHA.117.028814 · DOI
  22. Gerber, 2013, Contemporary trends in heart failure with reduced and preserved ejection fraction after myocardial infarction: a community study, Am J Epidemiol, 178, 1272, 10.1093/aje/kwt109 · DOI
  23. Bonow, 2016, Management strategies and future challenges for aortic valve disease, Lancet, 387, 1312, 10.1016/S0140-6736(16)00586-9 · DOI
  24. Nishimura, 2016, Mitral valve disease—current management and future challenges, Lancet, 387, 1324, 10.1016/S0140-6736(16)00558-4 · DOI
  25. Rodés-Cabau, 2016, Diagnosis and treatment of tricuspid valve disease: current and future perspectives, Lancet, 388, 2431, 10.1016/S0140-6736(16)00740-6 · DOI
  26. Yancy, 2017, J Am Coll Cardiol, 70, 776, 10.1016/j.jacc.2017.04.025 · DOI
  27. Shen, 2017, Declining risk of sudden death in heart failure, N Engl J Med, 377, 41, 10.1056/NEJMoa1609758 · DOI
  28. Komajda, 2017, Physicians' guideline adherence is associated with better prognosis in outpatients with heart failure with reduced ejection fraction: the QUALIFY international registry, Eur J Heart Fail, 19, 1414, 10.1002/ejhf.887 · DOI
  29. Ouwerkerk, 2017, Determinants and clinical outcome of uptitration of ACE-inhibitors and beta-blockers in patients with heart failure: a prospective European study, Eur Heart J, 38, 1883, 10.1093/eurheartj/ehx026 · DOI
  30. Epstein, 2015, Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors, Am J Manag Care, 21, S212
  31. Rossignol, 2011, J Am Coll Cardiol, 58, 1958, 10.1016/j.jacc.2011.04.049 · DOI
  32. Pitt, 2011, Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial, Eur Heart J, 32, 820, 10.1093/eurheartj/ehq502 · DOI
  33. Eschalier, 2013, Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure), J Am Coll Cardiol, 62, 1585, 10.1016/j.jacc.2013.04.086 · DOI
  34. Kirchhof, 2016, 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS, Eur Heart J, 37, 2893, 10.1093/eurheartj/ehw210 · DOI · Paper page
  35. Ferreira, 2016, Antithrombotic therapy in heart failure patients with and without atrial fibrillation: update and future challenges, Eur Heart J, 37, 2455, 10.1093/eurheartj/ehw213 · DOI
  36. Zannad, 2018, Rivaroxaban in patients with heart failure, sinus rhythm, and coronary disease, N Engl J Med, 379, 1332, 10.1056/NEJMoa1808848 · DOI · Paper page
  37. Ponikowski, 2015, Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiencydagger, Eur Heart J, 36, 657, 10.1093/eurheartj/ehu385 · DOI
  38. Komajda, 2014, Heart failure with preserved ejection fraction: a clinical dilemma, Eur Heart J, 35, 1022, 10.1093/eurheartj/ehu067 · DOI
  39. Owan, 2006, Trends in prevalence and outcome of heart failure with preserved ejection fraction, N Engl J Med, 355, 251, 10.1056/NEJMoa052256 · DOI
  40. Bhatia, 2006, Outcome of heart failure with preserved ejection fraction in a population-based study, N Engl J Med, 355, 260, 10.1056/NEJMoa051530 · DOI
  41. Dalos, 2016, Functional status, pulmonary artery pressure, and clinical outcomes in heart failure with preserved ejection fraction, J Am Coll Cardiol, 68, 189, 10.1016/j.jacc.2016.04.052 · DOI
  42. Kitzman, 2016, The HFpEF obesity phenotype: the elephant in the room, J Am Coll Cardiol, 68, 200, 10.1016/j.jacc.2016.05.019 · DOI
  43. Wolsk, 2018, Contribution of cardiac and extra-cardiac disease burden to risk of cardiovascular outcomes varies by ejection fraction in heart failure, Eur J Heart Fail, 20, 504, 10.1002/ejhf.1073 · DOI
  44. Campbell, 2014, Comorbidities and differential diagnosis in heart failure with preserved ejection fraction, Heart Fail Clin, 10, 481, 10.1016/j.hfc.2014.04.009 · DOI
  45. Solomon, 2005, Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients, Circulation, 112, 3738, 10.1161/CIRCULATIONAHA.105.561423 · DOI
  46. Shah, 2017, Heart failure with preserved, borderline, and reduced ejection fraction: 5-year outcomes, J Am Coll Cardiol, 70, 2476, 10.1016/j.jacc.2017.08.074 · DOI · Paper page
  47. Yusuf, 2003, Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial, Lancet, 362, 777, 10.1016/S0140-6736(03)14285-7 · DOI · Paper page
  48. Cleland, 2006, The perindopril in elderly people with chronic heart failure (PEP-CHF) study, Eur Heart J, 27, 2338, 10.1093/eurheartj/ehl250 · DOI
  49. Solomon, 2017, Angiotensin receptor neprilysin inhibition in heart failure with preserved ejection fraction: rationale and design of the PARAGON-HF trial, JACC Heart Fail, 5, 471, 10.1016/j.jchf.2017.04.013 · DOI
  50. Pfeffer, 2015, Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial, Circulation, 131, 34, 10.1161/CIRCULATIONAHA.114.013255 · DOI
  51. Hoendermis, 2015, Effects of sildenafil on invasive haemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension: a randomized controlled trial, Eur Heart J, 36, 2565, 10.1093/eurheartj/ehv336 · DOI
  52. Redfield, 2013, Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial, JAMA, 309, 1268, 10.1001/jama.2013.2024 · DOI
  53. Redfield, 2015, Isosorbide mononitrate in heart failure with preserved ejection fraction, N Engl J Med, 373, 2314, 10.1056/NEJMoa1510774 · DOI
  54. Solomon, 2012, The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial, Lancet, 380, 1387, 10.1016/S0140-6736(12)61227-6 · DOI
  55. Fitchett, 2018, Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME(R) trial, Eur Heart J, 39, 363, 10.1093/eurheartj/ehx511 · DOI · Paper page
  56. Radholm, 2018, Canagliflozin and heart failure in type 2 diabetes mellitus: results from the CANVAS program (Canagliflozin Cardiovascular Assessment Study), Circulation, 138, 458, 10.1161/CIRCULATIONAHA.118.034222 · DOI · Paper page
  57. Redfield, 2016, Heart failure with preserved ejection fraction, N Engl J Med, 375, 1868, 10.1056/NEJMcp1511175 · DOI
  58. Reddy, 2018, A simple, evidence-based approach to help guide diagnosis of heart failure with preserved ejection fraction, Circulation, 10.1161/CIRCULATIONAHA.118.034646 · DOI
  59. Heidenreich, 2013, Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association, Circ Heart Fail, 6, 606, 10.1161/HHF.0b013e318291329a · DOI
  60. Christ, 2016, Heart failure epidemiology 2000–2013: insights from the German Federal Health Monitoring System, Eur J Heart Fail, 18, 1009, 10.1002/ejhf.567 · DOI
  61. Omersa, 2016, National trends in heart failure hospitalization rates in Slovenia 2004–2012, Eur J Heart Fail, 18, 1321, 10.1002/ejhf.617 · DOI
  62. Solomon, 2007, Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure, Circulation, 116, 1482, 10.1161/CIRCULATIONAHA.107.696906 · DOI · Paper page
  63. Kristensen, 2015, Comparison of outcomes after hospitalization for worsening heart failure, myocardial infarction, and stroke in patients with heart failure and reduced and preserved ejection fraction, Eur J Heart Fail, 17, 169, 10.1002/ejhf.211 · DOI
  64. Crespo-Leiro, 2016, European Society of Cardiology Heart Failure Long-Term Registry (ESC-HF-LT): 1-year follow-up outcomes and differences across regions, Eur J Heart Fail, 18, 613, 10.1002/ejhf.566 · DOI · Paper page
  65. Chioncel, 2017, Clinical phenotypes and outcome of patients hospitalized for acute heart failure: the ESC Heart Failure Long-Term Registry, Eur J Heart Fail, 19, 1242, 10.1002/ejhf.890 · DOI
  66. Arrigo, 2017, Precipitating factors and 90-day outcome of acute heart failure: a report from the intercontinental GREAT registry, Eur J Heart Fail, 19, 201, 10.1002/ejhf.682 · DOI
  67. Ferrari, 2018, Acute heart failure: lessons learned, roads ahead, Eur J Heart Fail, 20, 842, 10.1002/ejhf.1169 · DOI
  68. Harjola, 2017, Organ dysfunction, injury and failure in acute heart failure: from pathophysiology to diagnosis and management. A review on behalf of the Acute Heart Failure Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC), Eur J Heart Fail, 19, 821, 10.1002/ejhf.872 · DOI
  69. Mebazaa, 2015, Eur J Heart Fail, 17, 544, 10.1002/ejhf.289 · DOI
  70. Gayat, 2018, Heart failure oral therapies at discharge are associated with better outcome in acute heart failure: a propensity-score matched study, Eur J Heart Fail, 20, 345, 10.1002/ejhf.932 · DOI
  71. Cheema, 2018, Lessons learned in acute heart failure, Eur J Heart Fail, 20, 630, 10.1002/ejhf.1042 · DOI
  72. Packer, 2018, Acute heart failure is an event rather than a disease: plea for a radical change in thinking and in therapeutic drug development, JACC Heart Fail, 6, 73, 10.1016/j.jchf.2017.05.008 · DOI
  73. Mebazaa, 2018, Acute heart failure deserves a log-scale boost in research support: call for multidisciplinary and universal actions, JACC Heart Fail, 6, 76, 10.1016/j.jchf.2017.09.012 · DOI
  74. Cooper, 2015, Consistency of laboratory monitoring during initiation of mineralocorticoid receptor antagonist therapy in patients with heart failure, JAMA, 314, 1973, 10.1001/jama.2015.11904 · DOI
  75. Nilsson, 2018, A real-world cohort study on the quality of potassium and creatinine monitoring during initiation of mineralocorticoid receptor antagonists in patients with heart failure, Eur Heart J Qual Care Clin Outcomes, 10.1093/ehjqcco/qcy019 · DOI
  76. McAlister, 2004, Multidisciplinary strategies for the management of heart failure patients at high risk for admission: a systematic review of randomized trials, J Am Coll Cardiol, 44, 810
  77. Alla, 2018, Impact of the interruption of a large heart failure regional disease management programme on hospital admission rates: a population-based study, Eur J Heart Fail, 20, 1066, 10.1002/ejhf.1193 · DOI
  78. Laborde-Casterot, 2016, Effectiveness of a multidisciplinary heart failure disease management programme on 1-year mortality: prospective cohort study, Medicine (Baltimore), 95, e4399, 10.1097/MD.0000000000004399 · DOI
  79. Agrinier, 2013, Effectiveness of a multidimensional home nurse led heart failure disease management program—a French nationwide time-series comparison, Int J Cardiol, 168, 3652, 10.1016/j.ijcard.2013.05.090 · DOI
  80. Hernandez, 2010, Relationship between early physician follow-up and 30-day readmission among Medicare beneficiaries hospitalized for heart failure, JAMA, 303, 1716, 10.1001/jama.2010.533 · DOI · Paper page
  81. Sarwar, 2016, Hyperkalemia in heart failure, J Am Coll Cardiol, 68, 1575, 10.1016/j.jacc.2016.06.060 · DOI
  82. Fraiche, 2017, Moving beyond the walls of the clinic: opportunities and challenges to the future of telehealth in heart failure, JACC Heart Fail, 5, 297, 10.1016/j.jchf.2016.11.013 · DOI
  83. Boehmer, 2017, A multisensor algorithm predicts heart failure events in patients with implanted devices: results from the MultiSENSE study, JACC Heart Fail, 5, 216, 10.1016/j.jchf.2016.12.011 · DOI
  84. 2003, Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials, Lancet, 362, 1527, 10.1016/S0140-6736(03)14739-3 · DOI · Paper page
  85. Thomopoulos, 2016, Effects of blood pressure-lowering treatment. 6. Prevention of heart failure and new-onset heart failure—meta-analyses of randomized trials, J Hypertens, 34, 373, 10.1097/HJH.0000000000000848 · DOI
  86. Butler, 2017, The potential role and rationale for treatment of heart failure with sodium-glucose co-transporter 2 inhibitors, Eur J Heart Fail, 19, 1390, 10.1002/ejhf.933 · DOI
  87. Preiss, 2015, The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trials, Eur Heart J, 36, 1536, 10.1093/eurheartj/ehv072 · DOI · Paper page
  88. Djousse, 2009, Relation between modifiable lifestyle factors and lifetime risk of heart failure, JAMA, 302, 394, 10.1001/jama.2009.1062 · DOI
  89. Ferreira, 2018, Rationale of the FIBROTARGETS study designed to identify novel biomarkers of myocardial fibrosis, ESC Heart Fail, 5, 139, 10.1002/ehf2.12218 · DOI

Cited by

Sorted by citations

Metadata

Authors
Rossignol, P., Hernandez, A. F., Solomon, S. D., & Zannad, F.
Venue
The Lancet
Publisher
Elsevier BV
Published
2019-03
Volume
393
Issue
10175
Pages
1034-1044
ISSN
0140-6736
DOI
10.1016/s0140-6736(18)31808-7
Cited by
316
References
15
Language
en
Licence
Funders
French National Research Agency (ANR-15-RHU-0004, ANR-15-IDEX-04-LUE)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review